Allogeneic haematopoietic stem cell transplantation (allo-HSCT) entails long-term morbidities that impair survivors' quality of life through broad physical and psychosocial sequelae. Current data and survival measurements may be inadequate for contemporary Australian allo-HSCT recipients. This study sought to comprehensively describe survivorship in an up-to-date, local setting through validated measurements and a novel questionnaire designed to complement and address limitations of current instruments. All adults who received an allo-HSCT between 2000 and 2012 in New South Wales were eligible and included, if alive, those literate and consenting to the study, which encompassed seven survey instruments. Four hundred and forty-three survivors participated, which is 76% of contactable (n = 583) and 66% of eligible survivors (n = 669). Chronic GVHD (cGVHD) and co-morbidity rates were similar to published data. Noteworthy results include prevalent sexual dysfunction (66% females, 52% males), loss of income (low income increased from 21 to 36%, P o 0.001) and employment (full-time employment fell from 64 to 33%, Po 0.001), suboptimal vaccination (31% complete), and health screening (≈50%). Risk factors for poor vaccination and health screening were cGVHD, younger age, less education, rural/regional residence and transplantation o2 years. This study suggests that improvement in survivorship may necessitate structural changes in the current delivery of health services.
INTRODUCTION
Over the past two decades, advances in allogeneic haematopoietic stem cell transplantation (allo-HSCT) have led to concomitant increases in the number of people undergoing this procedure and improvement in survivorship. Between 2001 and 2011, 90 000 alloHSCTs were performed globally, 1 with 4369 of them performed in Australia. 2 With improvements in donor selection, conditioning therapies and supportive care, more recipients are living longer, 3 and up to 85% are expected to be alive at 10 years. 4, 5 Although allo-HSCT provides a clear benefit, it is associated with significant morbidity and mortality. 6 A range of complications may occur anytime post transplant, including 'early' ( o3 months), 'delayed' (3 months to 2 years), 'late' (2-10 years) and 'very late' (410 years). 7 Although contemporary allo-HSCT recipients are living longer than historical cohorts, published data suggest that allo-HSCT survivors experience a 30% lower life expectancy than a matched population 6 and may experience a compromised quality of life (QoL) owing to the ongoing physical and psychological sequelae of cumulative therapies, 8, 9 failure to reintegrate socially 10, 11 and uncertainty of prognosis. 12 International and local bodies have recognised that research into the health, psychological and functional status of survivors is necessary to identify and address unmet needs of survivors and their families, enable better education and decisionmaking around BMT and inform the design and delivery of multidisciplinary health services essential to the care of long-term survivors. [13] [14] [15] This provides the rationale both for international and national registry studies of survivorship and 'local' studies of the specific experience of allo-HSCT survivors.
This study sought to comprehensively describe contemporary allo-HSCT survivorship in an Australian population with the intention of providing up-to-date information to candidates for allo-HSCT, their families and/or guardians regarding the long-term sequelae of allo-HSCT, supporting local clinical and health policy decision-making around allo-HSCT and optimising the care of survivors. Specifically, the aims of this study were to document the incidence and range of late complications and their association with the health and functional status of allo-HSCT survivors, address limitations in the current literature around survivorship, particularly with regards to the financial, occupational and psychosocial impact of allo-HSCT, and identify gaps in the existing care of survivors in New South Wales (NSW), Australia. the researchers. Patients who agreed received a study pack at the clinic or through the post, which consisted of an invitation letter, patient information sheet, consent form, the questionnaire and a stamped selfaddressed envelope for return of the study instrument. All participants were given the option to complete the questionnaire themselves or via a phone interview with a researcher. To increase recruitment, a second phone call was made to participants who had not returned the survey within a month. This study was approved by the Northern Sydney Local Health District Research Ethics Committee (NSLHD Reference: 1207-217M).
Instruments
Researchers collated information from transplant databases on diagnosis, disease status and date of transplantation, conditioning regimen, GVHD prophylaxis, stem cell source, and donor type for each consenting participant. All other information was obtained from patient's selfreported responses to the questionnaire. Participants completed a 20-page document that amalgamated seven survey instruments: The Sydney Post BMT Study survey (SPBS)-a questionnaire uniquely developed by the research team-and six other instruments previously validated in allo-HSCT populations including the Functional Assessment of Cancer TherapyBone Marrow Transplant (FACT-BMT Version 4), 17, 18 the Chronic GVHD Activity Assessment-Patient Self Report (Form B), 19 the Lee Chronic GVHD Symptom Scale, 20 the Depression Anxiety and Stress Scale (DASS21), 21 the Post Traumatic Growth Inventory (PTGI) 22 and the Fear of Recurrence Scale. 23 The Sydney Post BMT Study survey (SPBS) was uniquely designed by the research team to address limitations in existing post-transplant assessments to provide a more comprehensive account of survival. Item construction was informed by a review of the literature, interdisciplinary collaboration among health professionals involved in long-term care of allo-HSCT survivors and consultation with transplant recipients and their carers. There were 402 questions covering 20 domains, including demographics, medical complications, referrals/investigations, pharmaand non-pharmacotherapy, oral/dental health, infections, vaccinations, complementary therapy, cancer screening, travel history, close personal contacts, lifestyle, nutrition, infection risk, work status, fertility and sexual function, relationships, long-term follow-up care, psychosocial concerns and a qualitative question 'What are the three things that have impacted you most?'. The questionnaire used tick box response, short answer questions and 5-step Likert Scale measuring attitudes and other factors. The questionnaire was piloted in clinic and phone interviews to assess face and content validity and to check for comprehension of the survey questions.
Statistical analysis
Exploratory analyses of all demographic data, baseline transplant characteristics, and post-transplant exposures and lifestyle factors were summarised using descriptive statistics. Categorical responses were summarised using frequencies and percentages. Parametric continuous variables were summarised using means and SDs, and non-parametric variables using medians and interquartile ranges. The Pearson Chi-square or Fisher's0 Exact tests were used for dichotomous categorical variables and Pearson's correlation coefficient to assess the relationships between continuous variables. The McNemar test was used to assess for significant differences in the distribution of pre-transplant and post transplant dichotomous variables. Comparisons of means and medians were determined by the independent t-test and Wilcoxon Rank Sum tests for two samples; one-way analysis of variance and Kruskal Wallis tests were used when there were 42 samples. Multivariable logistic regression was used to assess for significant associations between explanatory and outcome variables after adjusting for potential confounders. A two-tailed P value o0.05 was considered as the level of statistical significance.
Statistical analysis was performed using STATA 12.1 statistical package (StataCorp, College Station, TX, USA).
RESULTS
There were 1475 allo-HSCT performed during the study period. There were 669 recipients alive at study sampling. Of the survivors, 583 were contactable and were sent study packs. Surveys were completed and returned by 443 (66%); while 17 (3%) declined consent and 125 (21%) did not return the survey.
Demographics and transplant characteristics are summarised in Table 1 .
Post-allo-HSCT morbidities are detailed for cGVHD (Table 2) , chronic morbidities including secondary malignancies (Table 3) , and infectious disease (Supplementary Table 1 ). Summarily, cGVHD was common (69.3%) and self-reported symptoms were moderate-severe in 32.4%. Skin, eye, vagina and mouth were the most symptomatic. The most reported chronic morbidities following allo-HSCT were iron overload (32.5%), osteoporosis/ osteopenia (29.1%), hypertension (28.9%) and cataracts (28.9%). Depression and anxiety were reported by 23.3% and 20.6%, respectively. The most frequently reported infections were influenza (38.4%) and herpes zoster (27.9%). A diagnosis of one or more malignancies following allo-HSCT was reported by 24%. The odds for having chronic co-morbidities were compared between those who have cGVHD (n = 301) and those without cGVHD (n = 133) (Supplementary Table 2 ). cGVHD increased the odds of co-morbidities, most significantly for osteoporosis/ osteopenia (odds ratio (OR) 1.85, P = 0.01), cataracts (OR 2.26, P = 0.001), recurrent upper respiratory tract infections (OR 1.86, P = 0.02), diabetes mellitus (OR 2.10, P = 0.03) and anxiety (OR 1.86, P = 0.03).
Vaccination and health screening uptake are described in Table 4 . Assessed screening were the Australian Government's Department of Health national screening for breast carcinoma (women 50-74 years), cervical (sexually active women between 18 and 70 years) and bowel carcinoma (450 years). Briefly, 52.3% had skin checks, 63.4% and 53.3% of females had papanicolaou (PAP) smear and mammography, respectively, and 66% had regular dental reviews. Only 31.8% had completed transplant vaccinations recommended in the first 12 months post transplant. Allo-HSCT of 42 years was the only variable significantly different between survivors who were not at all vaccinated compared with those who received all inactivated vaccines; survivors 42 years post allo-HSCT were much more likely to be vaccinated than early survivors (adjusted OR 12.2, 95% confidence interval 3.1-49.0, P = 0.001). Age (P = 0.93), gender (P = 0.11), income (P = 0.9), rural residence (P = 0.71), marital status (P = 0.26), education (P = 0.31) and cGVHD (P = 0.21) had no effect on vaccination. Polypharmacy was common, 10% were on five and 21% were on six or more medications; Supplementary Table 3 details medication use.
Sexual dysfunction in allo-HSCT survivors was common. Although similar percentages of males and females resumed sexual activity post transplant (males 69.2%, females 68.5%), both genders reported high incidences of sexual difficulties. Two-thirds of females (66.4%) and half of males (51.5%) reported any sexual dysfunction. Being female increased the risk of post-transplant sexual dysfunction (OR 1.8, P = 0.01), particularly for decreased pleasure (OR 4.3, P o 0.0001), libido (OR 1.4, P = 0.002) and dyspareunia (OR 26.1, P o0.0001). Erectile dysfunction was reported by 76.6% of males with sexual difficulties.
Specialist medical referrals were common (89%), and the median number of specialty services referred was three. The commonest were dermatology (60.3%), ophthalmology (43.6%), respiratory (28.2%) and endocrinology (23%). Allied healthcare referrals were fewer, with 41% reporting follow-up with at least one allied health specialty; most commonly physiotherapy (24%), dietetics (23%) and clinical psychology (18%). Three-quarters (74.4%) of survivors expressed a preference for long-term followup through their transplant centres or a facility linked with their transplant centre including a satellite clinic or telemedicine facility, while a quarter preferred their primary/local haematologist or general practitioner.
Four hundred and twenty-one respondents reported household income before and following allo-HSCT. The proportion of those in the lowest household income strata increased from 21% pretransplant to 36% post transplant (McNemar χ 2 = 46.3, P o 0.001) (Figure 1a ). Pre-transplant and post-transplant employment status was reported by 404 patients. Two hundred and sixty-one (65%) were in full-time employment pre-transplant, which fell to 130 (32.5%) following allo-HSCT (McNemar χ 2 = 106.6, P o0.001). Importantly, ill-health as a cause for being unable to work increased from 3.4% prior to allo-HSCT to 13. (Table 5 ). The correlation between subscale and summary FACT-BMT test scores was highest for functional well-being (correlation coefficient = 0.89) and lowest for social well-being (correlation coefficient = 0.63). Across FACT-BMT domains, social well-being further demonstrated the lowest reliability, with Abbreviations: ATGAM = anti-thymocyte globulin; equine; Bu = busulfan; cGVHD = chronic GVHD; CSA = cyclosporine; Cy = cyclophosphamide; Etop = etoposide; FLAMSA = fludarabine, cytarabine, amsacrine; Flu = fludarabine; HL = Hodgkin's Lymphoma; MDS = myelodysplastic syndrome; MM = multiple myeloma; MMF = mycophenolate mofotil; Mel = melphalan; MTX = methotrexate; NHL = non-Hodgkin's lymphoma; PBSCT = peripheral blood stem cell transplantation; Pred = prednisolone; SAA = severe aplastic anaemia; tacro = tacrolimus. This table summarizes characteristics of study participants.
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There were some differences between genders in personal growth following allo-HSCT measured by PTGI; females exhibited greater growth than males in relationship with others (P o0.001), personal strength (P o0.001) and spiritual growth (P o0.001).
DISCUSSION
This study is the largest and most comprehensive assessment of allo-HSCT survivorship in a contemporary Australian cohort. The results reveal a high incidence and broad range of physiological and psychosocial complications that adversely affect the health and functional status of survivors.
The incidence of cGVHD was 69% for the studied group, which is within reported ranges in the literature despite an older cohort (median age 54), utilisation of unrelated and mismatched donors (43.1%) and PBSC (86.4%). 1, 24, 25 Chronic physiological effects were common with 57% of the study group reporting two or more active medical co-morbidities. Importantly, cGVHD increased the odds of chronic medical and psychological sequelae, particularly osteoporosis/osteopenia, diabetes mellitus, cataracts, recurrent respiratory tract infections and anxiety.
After cGvHD, sexual dysfunction was the most adversely affected domain following allo-HSCT reported by allo-HSCT survivors in this study. Over 95% of study participants provided insight into resumption of sexual activity following allo-HSCT, which was similar between males and females (69%). Approximately 60% of respondents reported sexual difficulties post transplant (66.4% females, 51.5% males). As sexual dysfunction likely results from multiple chronic physical and psychological comorbidities, our results suggest the need for a comprehensive multidisciplinary approach to prevention and management that includes education of allo-HSCT candidates and partners prior to transplantation, ongoing assessment and counselling post transplant and early specialist referral to prevent delayed diagnosis and treatment. The psychosocial impact of allo-HSCT was profound, affected by loss of employment and reduced income. Social re-integration was modest, with significant underemployment, unemployment and non-return to work (most often as a consequence of chronic ill-health), and increase in the number of survivors in the lowest income bracket. Although strategies aimed at the prevention and treatment of chronic physical and psychological complications of allo-HSCT may improve social re-integration and minimise financial disenfranchisement, these are unlikely to completely ameliorate the psychosocial impacts of allo-HSCT. These results suggest potential transplant recipients should receive pretransplant and post transplant counselling and be directed to seek appropriate assistance to reorganise their finances and assets. This study shows that 'financial toxicity' is an adverse effect of allo-HSCT that should be considered on par with other longterm effects. In addition, financial stress may contribute to nonadherence and lifestyle modifications that are detrimental to a survivor's QoL. 26 A graded, objective measure of financial toxicity is needed. 27, 28 Improvements in vaccination and uptake of screening following allo-HSCT are urgently needed. Less than a third of respondents had completed the recommended post-transplant vaccination schedule, and this is reflected by a high incidence of vaccinepreventable diseases (42%). These alarming statistics suggests that current systems are resulting in an unacceptably high 'miss' rate and arguably mandate a change in vaccination promotion and delivery. Furthermore, national immunisation guidelines for allo-HSCT and other transplant recipients have been available and published within the most recent editions of the national Australian Immunisation handbook that is easily accessible to the public and healthcare workers. In this regard, it is noteworthy that in multivariate analysis, demographic differences and the presence of cGVHD had no effect on vaccination uptake, whereas those who had an allo-HSCT for over 2 years were 12 times more likely to be vaccinated. The results suggest that there are barriers to vaccination during the first 2 years post transplant and that these are unrelated to the presence or severity of cGvHD or to baseline demographics. Of those who had received vaccinations (31% complete, 51% partial), three-quarters were administered by general practitioners-an important reminder both of the importance of primary/local healthcare providers in the longterm care of allo-HSCT recipients and of the need for ongoing communication with, and education of, health practitioners involved in the care of survivors. 29, 30 That said, the fact that most allo-HSCT survivors receive post-transplant care through their transplant centre and express a preference for centrally coordinated care suggests that long-term follow-up clinics may need to provide post transplant vaccination service, at the very least for survivors who do not have a general practitioner.
Other health screenings assessed in the study were also suboptimal. Only 52% of respondents had routine skin checks, a disappointing response given the high incidence of skin malignancies following allo-HSCT and the high background incidence of both melanoma and non-melanoma cancers in Australia. 31, 32 Likewise, only 63% and 53%, respectively, of female survivors of allo-HSCT had had recommended PAP smear cervical carcinoma screening and 53% screening mammography. Just twothirds of survivors have regular dental/oral reviews; older age, higher income and residing in a metropolitan area were predictors of regular dental review. Non-attendance was reported to be due to finances by a third and due to thinking that dental reviews were unnecessary by another third. There is an urgent need for education about the long-term effects of oral health following allo-HSCT. These results may also evidence systemic failings as it is well recognised that there are a number of financial and structural barriers that prevent Australians accessing affordable dental care; Table 5 . Experience of survival following allo-HSCT in NSW, Australia G Gifford et al with a 2010 Australian Institute of Health and Research survey reporting that 30% of adults avoided dentists owing to costs (http://www.aihw.gov.au/dental/cost/). Although there are public dental services in New South Wales, and some transplant centres have access to hospital-based dental clinics, the waiting times are long and the location inconvenient for many survivors. Summarily, these results suggest that survivors with cGVHD should receive additional psychological intervention, dedicated screening and aggressive prevention and treatment of osteoporosis/ostepenia and diabetes mellitus. Other groups identified in need of additional focus to reinforce and improve health screening are younger transplant recipients, those with less education, those in the 'early' post-transplant period and survivors residing in rural/regional Australia.
Although the large number of participating survivors, high response rate, multi-centre cohort and comprehensive assessment makes it likely that these results represent an accurate account of the experience of contemporary survivors of allo-HSCT in Australia, there are a number of factors that may limit the generalisability of these results to allo-HSCT survivors in other countries and settings.
First, despite the high response rate (76%), participation was incomplete resulting in possible participation bias. Second, the study was a cross-sectional study that included only those alive at study recruitment, thereby excluding those who may have died because of post-transplant complications, which may have been more rapidly progressive or highly lethal. Third, the use of a questionnaire as the research methodology has well-recognised inherent limitations, including recall and misclassification biases that, despite piloting, the use of validated instruments and simple English, could potentially limit self-reported response internal validity. Misclassification biases may go in either directions, thereby over-estimating or under-estimating effects. Fourth, the veracity of participants' responses was not compared with medical records, which may compromise factorial validity. Fifth, the questionnaire could not distinguish between the effects of cGVHD from complications of its treatment-a limitation that may be of no consequence to the study of chronic health, as most survivors with cGVHD require prolonged immunosuppression. Sixth, the respondents to this study were disproportionately white/Caucasians (86.9%), thus limiting the ability to generalise to other ethnic groups.
This study provides the largest and most comprehensive account of the incidence and range of late complications following allo-HSCT in a contemporary population of Australian survivors. For the most part, the incidence of cGVHD and chronic post transplant co-morbidities were similar to that reported in available literature. 6, 24, 25 Our results also reveal the extent to which allo-HSCT transforms the lives of survivors-causing psychological, social and sexual dysfunction, financial insecurity and occupational vulnerability in many survivors. Perhaps most worryingly, this study also suggests that the care of allo-HSCT recipients is deficient in many ways, with suboptimal health screening, dental care and vaccination uptake as areas of unmet need in Australian allo-HSCT survivors. Addressing these deficiencies will clearly require a multidisciplinary approach and may necessitate changes in the delivery of healthcare to Australian patients. Extrapolating from paediatric experiences [33] [34] [35] and overseas models (such as the Fred Hutchison Cancer Research Centre/Seattle Cancer Care Alliance or MD Anderson Cancer Centre in the United States), 30 centralized co-ordination through a long-term follow-up survivor's clinic may best address inadequacies of the current system. Such structures may avoid fragmentation of services and provides continuity of care, both of which are essential to address complex problems such as sexual dysfunction and adherence/compliance with health promotion. But the success of such a service cannot be assumed and would need to be the focus of ongoing research. Irrespective of what model of care proves to be most effective, the results of this study make clear that as allo-HSCT recipients live longer, the focus of care and resources must proportionately shift to improving their QoL and optimising their experience of survivorship.
